Relevant bibliographies by topics / NEUROPROTECTANTS

Academic literature on the topic 'NEUROPROTECTANTS'

Author: Grafiati
Published: 11 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'NEUROPROTECTANTS.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "NEUROPROTECTANTS"

1

Palmer, Katharine J., and Joanne Dalton. "Neuroprotectants in Stroke." Drugs in R & D 1, no. 1 (January 1999): 9–13. http://dx.doi.org/10.2165/00126839-199901010-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schreihofer, D. A. "Phytoestrogens as neuroprotectants." Drugs of Today 45, no. 8 (2009): 609. http://dx.doi.org/10.1358/dot.2009.45.8.1395520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shi, Ligen, Marcelo Rocha, Rehana K. Leak, Jingyan Zhao, Tarun N. Bhatia, Hongfeng Mu, Zhishuo Wei, et al. "A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion." Journal of Cerebral Blood Flow & Metabolism 38, no. 12 (September 7, 2018): 2073–91. http://dx.doi.org/10.1177/0271678x18798162.

Full text
Abstract:
Recent advances in stroke reperfusion therapies have led to remarkable improvement in clinical outcomes, but many patients remain severely disabled, due in part to the lack of effective neuroprotective strategies. In this review, we show that 95% of published preclinical studies on “neuroprotectants” (1990–2018) reported positive outcomes in animal models of ischemic stroke, while none translated to successful Phase III trials. There are many complex reasons for this failure in translational research, including that the majority of clinical trials did not test early delivery of neuroprotectants in combination with successful reperfusion. In contrast to the clinical trials, >80% of recent preclinical studies examined the neuroprotectant in animal models of transient ischemia with complete reperfusion. Furthermore, only a small fraction of preclinical studies included long-term functional assessments, aged animals of both genders, and models with stroke comorbidities. Recent clinical trials demonstrate that 70%–80% of patients treated with endovascular thrombectomy achieve successful reperfusion. These successes revive the opportunity to retest previously failed approaches, including cocktail drugs that target multiple injury phases and different cell types. It is our hope that neurovascular protectants can be retested in future stroke research studies with specific criteria outlined in this review to increase translational successes.
APA, Harvard, Vancouver, ISO, and other styles
4

Sharkey, John, Paul A. Jones, Jennifer F. McCarter, and John S. Kelly. "Calcineurin Inhibitors as Neuroprotectants." CNS Drugs 13, no. 1 (January 2000): 1–13. http://dx.doi.org/10.2165/00023210-200013010-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jeyaseelan, K., KY Lim, and A. Armugam. "Neuroprotectants in stroke therapy." Expert Opinion on Pharmacotherapy 9, no. 6 (April 2008): 887–900. http://dx.doi.org/10.1517/14656566.9.6.887.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Štolc, Svorad. "Indole derivatives as neuroprotectants." Life Sciences 65, no. 18-19 (October 1999): 1943–50. http://dx.doi.org/10.1016/s0024-3205(99)00453-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kelly, J. S., and J. Sharkey. "Immunosuppressants-ligands as neuroprotectants." Transplantation Proceedings 33, no. 3 (May 2001): 2217–19. http://dx.doi.org/10.1016/s0041-1345(01)01945-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Muir, K. W., and Ph A. Teal. "Why have neuroprotectants failed?" Journal of Neurology 252, no. 9 (August 25, 2005): 1011–20. http://dx.doi.org/10.1007/s00415-005-0933-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Neuroprotectants for Parkinson's disease reviewed." Inpharma Weekly &NA;, no. 1389 (May 2003): 4. http://dx.doi.org/10.2165/00128413-200313890-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

KLEIN, MICHAEL, SILVIA CALDERON, and BELINDA HAYES. "Abuse Liability Assessment of Neuroprotectants." Annals of the New York Academy of Sciences 890, no. 1 NEUROPROTECTI (December 1999): 515–25. http://dx.doi.org/10.1111/j.1749-6632.1999.tb08033.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "NEUROPROTECTANTS"

1

Boice, Ashley. "DEVELOPMENT OF SMALL MOLECULE NEUROPROTECTANTS." VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5372.

Full text
Abstract:
Neurodegenerative diseases are a class of conditions that lead to progressive atrophy of different parts of the central nervous system (CNS). These diseases lead to devastating clinical outcomes to patients and give rise to an enormous socio-economical burden on society.1 One commonality among some of the most well-known neurodegenerative disorders, e.g. Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS), is neuroinflammation.2-4 Neuroinflammation stems from interactions of the innate immune system with toxins and insults to the central nervous system. In the case of irremovable or chronic insults and toxins, this leads to chronic damaging inflammation that hastens neuronal degeneration and exacerbates disease pathology.5,6 Recently, inflammasomes of the innate immune system have been indicated in playing essential roles in the observed inflammatory responses. The most studied inflammasome is the nod-like receptor pyrin containing 3 (NLRP3) inflammasome.7–9 Recently our research group has successfully developed sulfonamide-based small molecule inhibitors of the NLRP3 inflammasome, such as JC-21 and JC-171, as potential therapeutics for AD and MS. Our studies established that JC-21 is a selective inhibitor of the NLRP3 inflammasome.10,11 Structural modifications led to the development of JC-171 with improved pharmacokinetic properties. More importantly, our studies demonstrated the in vivo activity of JC-171 to effectively ameliorate the experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.12 Our data also strongly suggested that inhibitors based on this chemical scaffold may directly target the NLRP3 inflammasome.10–12 In this dissertation, we conducted biophysical, biochemical, and modeling studies to further elucidate the mechanistic information of these compounds as inhibitors of the NLRP3 inflammasome. In order to conduct further mechanistic studies, the NLRP3 protein was produced via transfection of HEK 293 cells with a modified plasmid of full-length human NLRP3 protein.13 Furthermore, LC-MS studies were conducted to confirm the blood-brain barrier penetration (BBB) of JC-171. Our studies established that JC-171 directly binds to the NLRP3 protein. The results also suggested that JC-171 may bind to the NACHT domain of NLRP3 while in a site that is distinct from the ATP binding site. This notion is supported by the fact that our compounds do not interfere with the ATPase activity of NLRP3. Docking studies of JC-171 to the homology model of the NACHT domain of NLRP3 also supported this assertion by showing the interaction of JC-171 with residues that are not overlapping with the ATP binding pocket. BBB penetration studies in combination with LC-MS analysis confirmed that JC-171 shows better BBB penetration when compared to MCC950. Collectively, our results strongly support that our compounds function as NLRP3 inflammasome inhibitors by directly binding to the NLRP3 protein, a novel and distinct mechanism of action when compared to the known inhibitors that target the NLRP3 inflammasome pathway. These results strongly encourage further development of such inhibitors as potential therapeutics for neurodegenerative diseases.
APA, Harvard, Vancouver, ISO, and other styles
2

Joshi, Kaushal V. "Novel Neuroprotectants for Sarin plus CBDP induced convulsions." Wright State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=wright1253321185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Zai Jun. "Pharmacological characterization of new neuroprotectants in Parkinson's disease models." Thesis, University of Macau, 2012. http://umaclib3.umac.mo/record=b2554086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nandasena, Charith. "Impact of neuroprotectants on behavioural and cognitive loss in neurodegenerative diseases." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/17235.

Full text
Abstract:
The discovery of amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations associated with hereditary Alzheimer’s disease (AD) was a fundamental step in the development of rodent models to investigate its underlying pathology. This project examined the effects of pre-treatment with photobiomodulation (PBM) or saffron on learning and memory of the APP/PS1 double transgenic mouse using the Intellicage system which allows fully automated continuous testing of behaviour in a home cage environment. Protocols covering exploration, place and place reversal learning, and drinking behaviours were used to characterize longitudinal behaviours. Transgenic mice were successful in learning and re-learning tasks and showed inconsistent effects from both saffron and PBM treatment which may have been influenced by group housing of transgenic and wild-type mice. In contrast when brains were examined by histological analysis at the conclusion of behavioural experiments, it was evident that both PBM and saffron treatment mitigated Aß deposition in the aging APP/PS1 mice. This correlated with reduced mitochondrial dysfunction and saffron pre-treatment also reduced oxidative damage. The mitigation of these three major pathological hallmarks of Alzheimer’s disease – amyloid-ß plaque pathology, oxidative stress and mitochondrial dysfunction, by PBM and saffron treatment reinforces their potential as viable neuroprotective treatments for chronic neurodegenerative conditions. This work emphasises the importance of behavioural testing of animal models in the assessment of treatments and that dietary saffron and PBM are effective, safe, easily administered and minimally invasive interventions to treat chronic neurodegenerative disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Clarke, Allison Elizabeth. "Novel organic nitrates as possible neuroprotectants in an in vitro model of stroke in the rat hippocampus." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/MQ59369.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fu, Qingling. "Characterization of novel neuroprotectants for rescuing retinal ganglion cell loss in an ocular hypertensive model of glaucoma." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/HKUTO/record/B39557510.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fu, Qingling, and 付清玲. "Characterization of novel neuroprotectants for rescuing retinal ganglion cell loss in an ocular hypertensive model of glaucoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2007. http://hub.hku.hk/bib/B39557510.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wong, Raymond. "Progesterone as a neuroprotectant in stroke." Thesis, University of Nottingham, 2013. http://eprints.nottingham.ac.uk/13730/.

Full text
Abstract:
Progesterone has been shown to be neuroprotective in a number of central nervous system injury models, including cerebral ischaemia. There is still a lack of understanding behind progesterone’s neuropotective properties, and the purpose of this project is to clarify some of these issues. Osmotic mini-pump infusion was hypothesised to more effective in delivering progesterone to the target organ of the brain, when compared to a bolus intraperitoneal injection. Progesterone pharmacokinetic profiles were compared between different dosing regimes. Intraperitoneal progesterone injection had a short half-life in both plasma and brain, while osmotic mini-pumps delivered higher concentrations of progesterone in plasma and particularly in brain, over a longer period, which supports the hypothesis. It was hypothesised that progesterone will reduce NO production and cell death in in vitro. Progesterone reduced nitric oxide production after challenging microglia with LPS, which supports our hypothesis and the nuclear progesterone receptor was found not to have a major role in nitric oxide attenuation. Neither of the microglial cell lines, BV-2 and HAPI cells produced elevations in NO formation in ischaemic conditions. The in vitro oxygen and glucose deprived model of ischaemia, reduced viability in both microglial and neuronal cells. Also, high pharmacological concentrations of progesterone exacerbated ischaemic injury, which does not support the hypothesis of progesterone in reducing cell death. Progesterone administration, via osmotic mini-pump infusion, was hypothesised to have a better outcome compared to vehicle treatment. After the onset of experimental stroke, progesterone delivery via osmotic mini-pump with loading dose was found to be beneficial in terms of neurological deficit score in adult male mice, which supports the hypothesis. Also, we hypothesise that co-morbidity can affect the efficacy of progesterone treatment in outcomes. Aged animals have an increased sensitivity to experimentally induce stroke and did not display, in the outcomes measured, any benefit from progesterone treatment. NOD/ShiLtJ mice had severe symptoms, resulting in high mortality after surgery and are not recommended as a model of diabetes for experimental stroke. Hypertensive BPH/2 mice are a potential hypertensive model and had better functional outcomes after treatment with intraperitoneally administered progesterone, compared to non-treated hypertensive animals in our small preliminary study. This supports our hypothesis that co-morbidity can affect the efficacy of progesterone treatment in outcomes. The gold-standard for assessing intervention effects across studies within and between subgroups is to use meta-analysis based on individual animal data. We hypothesise meta-analysis would reveal progesterone to reduce lesion volume, but also discover other effects in different subgroups of animals. Progesterone significantly reduced lesion volume, it also appeared to increase the incidence of death following experimental stroke. Furthermore, this negative effect appears to be particularly apparent in young ovariectomised female animals. These findings support the hypothesis that progesterone reduces lesion volume and progesterone having other effects in different subgroups. This investigation has clarified some issues and expanded our understanding on the neuroprotective properties of progesterone. However, these findings indicate further investigation is still required before progesterone can be considered for use in clinical trials as a neuroprotectant in stroke.
APA, Harvard, Vancouver, ISO, and other styles
9

Park, Han-A. "Natural Vitamin E, α-Tocotrienol, as a Neuroprotectant." The Ohio State University, 2010. http://rave.ohiolink.edu/etdc/view?acc_num=osu1291061955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sawyer, Dale C. "The interactions of putative neuroprotectant compounds with NMDA ion channels." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq25152.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "NEUROPROTECTANTS"

1

Antkiewicz-Michaluk, Lucyna, and Hans Rommelspacher, eds. Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-1542-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Isoquinolines and beta-carbolines as neurotoxins and neuroprotectants: New vistas in Parkinson's disease therapy. New York: Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rommelspacher, Hans, and Lucyna Antkiewicz-Michaluk. Isoquinolines and Beta-Carbolines As Neurotoxins and Neuroprotectants: New Vistas in Parkinson's Disease Therapy. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Reich, David L., Stephan A. Mayer, and Suzan Uysal, eds. Neuroprotection in Critical Care and Perioperative Medicine. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190280253.001.0001.

Full text
Abstract:
Clinicians caring for patients are challenged by the task of protecting the brain and spinal cord in high-risk situations. These include following cardiac arrest, in critical care settings, and during complex procedural and surgical care. This book provides a comprehensive overview of various types of neural injury commonly encountered in critical care and perioperative contexts and the neuroprotective strategies used to optimize clinical outcomes. In addition to introductory chapters on the physiologic modulators of neural injury and pharmacologic neuroprotectants, the topics covered include: imaging assessment; tissue biomarker identification; monitoring; assessment of functional outcomes and postoperative cognitive decline; traumatic brain injury; cardiac arrest and heart-related issues such as valvular and coronary artery bypass surgery, aortic surgery and stenting, and vascular and endovascular surgery; stroke; intracerebral hemorrhage; mechanical circulatory support; sepsis and acute respiratory distress syndrome; neonatal issues; spinal cord injury and spinal surgery; and issues related to general, orthopedic, peripheral vascular, and ear, nose and throat surgeries.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "NEUROPROTECTANTS"

1

Uhr, M., B. Moosmann, and C. Behl. "Aromatic alcohols as neuroprotectants." In Alzheimer’s Disease — From Basic Research to Clinical Applications, 287–94. Vienna: Springer Vienna, 1998. http://dx.doi.org/10.1007/978-3-7091-7508-8_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Andrews, Anne M., Greg A. Gerhardt, Lynette C. Daws, Mohammed Shoaib, Barbara J. Mason, Charles J. Heyser, Luis De Lecea, et al. "Neuroprotectants: Novel Approaches for Dementias." In Encyclopedia of Psychopharmacology, 856–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rhodes, Kenneth J. "Neuroprotectants: Novel Approaches for Dementias." In Encyclopedia of Psychopharmacology, 1073–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-36172-2_401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rhodes, Kenneth J. "Neuroprotectants: Novel Approaches for Dementias." In Encyclopedia of Psychopharmacology, 1–5. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27772-6_401-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Vetiska, Sandra M., and Michael Tymianski. "Neuroprotectants Targeting NMDA Receptor Signaling." In Handbook of Neurotoxicity, 1381–402. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-5836-4_168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dada, Tanuj, Parul Ichhpujani, Srinivasan Senthilkumari, and Alain Bron. "Ocular Hypotensives and Neuroprotectants in Glaucoma." In Pharmacology of Ocular Therapeutics, 207–27. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-25498-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Grotta, James C., and Lise A. Labiche. "Combination of Thrombolytic Therapy With Neuroprotectants." In Thrombolytic Therapy for Acute Stroke, 77–93. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-933-8:77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Alkayed, Nabil J., Michael M. Wang, and Patricia D. Hurn. "Reproductive Hormones as Neuroprotectants in Brain Injury." In Brain Injury, 295–315. Boston, MA: Springer US, 2001. http://dx.doi.org/10.1007/978-1-4615-1721-4_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Barreto, Andrew D., and James C. Grotta. "Combination of Thrombolytic Therapy with Antithrombotics and Neuroprotectants." In Thrombolytic Therapy for Acute Stroke, 65–80. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07575-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lorenc-Koci, Elżbieta. "Two Faces of 1,2,3,4-Tetrahydroisoquinoline Mode of Action in the Mammalian Brain: Is It an Endogenous Neurotoxin or a Neuromodulator?" In Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants, 3–30. Boston, MA: Springer US, 2011. http://dx.doi.org/10.1007/978-1-4614-1542-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "NEUROPROTECTANTS"

1

Gourley, Paul L., P. Chen, R. G. Copeland, Judy K. Hendricks, Anthony E. McDonald, M. E. Keep, and J. R. Karlsson. "Nanosqueezed light for probing mitochondria and calcium-induced membrane swelling for study of neuroprotectants." In Micromachining and Microfabrication, edited by Peter Woias and Ian Papautsky. SPIE, 2004. http://dx.doi.org/10.1117/12.532188.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "NEUROPROTECTANTS"

1

Gourley, Paul Lee, Robert Guild Copeland, Anthony Eugene McDonald, Judy K. Hendricks, and Robert K. Naviaux. Quantum squeezed light for probing mitochondrial membranes and study of neuroprotectants. Office of Scientific and Technical Information (OSTI), January 2005. http://dx.doi.org/10.2172/921140.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bahr, Ben A. Comparison of Novel and Known Neuroprotectants for Treating Exposure to Different Types of Toxins. Fort Belvoir, VA: Defense Technical Information Center, September 2002. http://dx.doi.org/10.21236/ada416987.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bahr, Ben A. Comparison of Novel and Known Neuroprotectants for Treating Exposure to Different Types of Toxins. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada419303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bahr, Ben A. Comparison of Novel and Known Neuroprotectants for Treating Exposure to Different Types of Toxins. Fort Belvoir, VA: Defense Technical Information Center, September 2000. http://dx.doi.org/10.21236/ada384358.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Saukkonen, Jussi. Xenon as a Neuroprotectant in Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, March 2012. http://dx.doi.org/10.21236/ada581238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Saukkonen, Jussi. Xenon as a Neuroprotectant in Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, September 2011. http://dx.doi.org/10.21236/ada601955.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Saukkonen, Jussi, and Bruce Kristal. Xenon as a Neuroprotectant in Traumatic Brain Injury. Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada547294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'NEUROPROTECTANTS' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography